Novartis CEO Vasant Narasimhan, MD, told Bloomberg it’s the right time to examine whether Sandoz strategically fits into the company. Sandoz’s low sales were largely attributed to the reduced cold and flu season that resulted from COVID-19 safety measures, Narasimhan said.
Novartis’ review of Sandoz, one of the largest generic drugmakers in the world, follows the move it made in 2019 to spin off Alcon, its eye care unit.
The drugmaker is seeking to deepen its focus on new treatments for cancer and other diseases, according to the report.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
